insight
← 뒤로

Impact of intravenous tranexamic acid administration on reduction mammoplasty outcomes.

JPRAS open 2026 Vol.48() p. 722-734

Francalancia S, Lou M, Leeke K, Wang M, McIntire D, Sobti N, Kwan D, Roussel L, Maselli A, Sullivan R, Liu P, Breuing K

PMC 전문 ↗ 원문 ↗ DOI ↗

관련 도메인

트라넥삼산 Tranexamic Acid 유방성형술 Mammoplasty 흉터교정술 Scar Revision 유방 Breast 상처열개 Dehiscence

Abstract

[BACKGROUND] The growing use of tranexamic acid (TXA) in plastic surgery warrants an accurate analysis of efficacy for body contouring indications. We offer the largest cohort evaluation of intravenous TXA use in minimizing postoperative complications following reduction mammoplasty.

[METHODS] A single-institution retrospective analysis was conducted on consecutive reduction mammoplasty procedures performed between February 2023-August 2024. Patient demographics, intraoperative factors, and postoperative complications were collected and summarized using descriptive statistics. Groups were stratified based on administration of TXA, with differences assessed using Pearson's chi-square test for categorical variables and Student's -test or Wilcoxon rank sum test for continuous variables, as appropriate. Association of perioperative intravenous TXA use with postoperative complications was analyzed by breast with multivariable logistic regression.

[RESULTS] Of 406 patients (812 breasts), 213 patients (426 breasts) were administered TXA perioperatively. Neither group had significant differences in Caprini score, prior history of DVT, or anemia. Multivariable regression analysis, controlling for differences in demographics and operative characteristics, demonstrated that TXA use was significantly associated with decreased rates of dehiscence (aOR = 0.50, 95% CI 0.28-0.91, = 0.023) and scar revision (aOR = 0.30, 95% CI 0.12-0.76, = 0.015). Among breasts that were only closed with barbed sutures, after adjustment for demographics and operative characteristics, TXA use was significantly associated with lower rates of scar revision only (aOR = 0.16; 95% CI 0.05-0.52; = 0.005).

[CONCLUSION] Intravenous TXA use in reduction mammoplasty confers lower rates of postoperative wound complications, though its impact may be secondary to wound closure technique.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
약물 txa 트라넥삼산 dict 8
시술 reduction mammoplasty 유방성형술 dict 4
시술 scar revision 흉터교정술 dict 2
약물 tranexamic acid 트라넥삼산 dict 2
해부 intravenous TXA use in scispacy 1
해부 intravenous TXA use with scispacy 1
해부 breasts scispacy 1
해부 breast 유방 dict 1
합병증 scar scispacy 1
합병증 wound scispacy 1
합병증 dehiscence 상처열개 dict 1
약물 intravenous tranexamic acid scispacy 1
약물 [BACKGROUND] scispacy 1
질환 812 breasts scispacy 1
질환 DVT C0149871
Deep Vein Thrombosis
 scispacy 1
질환 anemia C0002871
Anemia
 scispacy 1
질환 breasts C0006141
Breast
 scispacy 1
기타 Patient scispacy 1
기타 patients scispacy 1

📑 인용 관계

이 논문이 참조한 문헌 32

외부 PMID 21건 (DB 미수집)

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

피판재건술 (304) 피하조직 (169) 감염 (165) 복부성형술 (141) 지방흡입 (126) 피막구축 (121) 근막하 평면 (101) 코성형술 (92)

관련 논문